THE BENEFIT OF ATG IN IMMUNOSUPPRESSIVE THERAPY OF CHILDREN WITH MODERATE APLASTIC ANEMIA

被引：16

作者：

Jiang, Shayi ^{[1
]}

Wang, Yaoping ^{[2
]}

Shi, Wei ^{[1
]}

Shao, Yuexia ^{[1
]}

Qiao, Xiaohong ^{[1
]}

Lin, Jieliang ^{[1
]}

Kuang, Hanqin ^{[1
]}

Xie, Xiaotian ^{[1
]}

机构：

[1] Tongji Univ, Tongji Hosp, Dept Pediat, Shanghai 200092, Peoples R China

[2] Shanghai Childrens Hosp, Dept Hematol & Ocol, Shanghai 200040, Peoples R China

来源：

PEDIATRIC HEMATOLOGY AND ONCOLOGY | 2009年 / 26卷 / 05期

关键词：

antithymocyte globulin; aplastic anemia; pediatric; treatment; ANTITHYMOCYTE GLOBULIN; CYCLOSPORINE;

D O I：

10.1080/08880010902771549

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. Previous studies specifically focused on the immunosuppressive therapy (IST) of children with moderate aplastic anemia (MAA) are rare. The aim of this study was to evaluate the advantage of using antithymocyte globulin (ATG) in the IST and its outcome of children with MAA. Methods. Forty-two children diagnosed with moderate aplastic anemia from 1993 to 2006 were retrospectively reviewed. Eighteen patients treated with ATG, cyclosporin A (CSA), and androgen are defined as the ATG group, the other 24 patients treated with CSA and androgen are defined as the non-ATG group. Survival and hematological response of the two groups were studied. Results. Response rate and transfusion-independent survival of the ATG group were both significantly higher than those of the non-ATG group (83.33 vs. 41.7%, p = .006; and 83.33 vs. 50%, p = .043, respectively). Compared with non-ATG group, fewer patients in ATG group progress to severe aplastic anemia (p = .03). Conclusion. Immunosuppressive therapy including ATG benefits children with moderate aplastic anemia.

引用

页码：313 / 320

页数：8

共 11 条

[1] ANTI-THYMOCYTE GLOBULIN TREATMENT IN PATIENTS WITH APLASTIC-ANEMIA - A PROSPECTIVE RANDOMIZED TRIAL [J].

CHAMPLIN, R ;

HO, W ;

GALE, RP .

NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (03) :113-118

[2] TREATMENT OF APLASTIC-ANEMIA WITH CYCLOSPORINE-A, METHYLPREDNISOLONE, AND ANTITHYMOCYTE GLOBULIN [J].

FRICKHOFEN, N ;

HEIT, W ;

RAGHAVACHAR, A ;

PORZSOLT, F ;

HEIMPEL, H .

KLINISCHE WOCHENSCHRIFT, 1986, 64 (22) :1165-1170

[3] Natural history of moderate aplastic anemia in children [J].

Howard, SC ;

Naidu, PE ;

Hu, XJ ;

Jeng, MR ;

Rodriguez-Gallindo, C ;

Rieman, MD ;

Wang, WC .

PEDIATRIC BLOOD & CANCER, 2004, 43 (05) :545-551

[4]

KHATIB Z, 1994, AM J PEDIAT HEMATOL, V16, P80

[5] Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia [J].

Maciejewski, JP ;

Sloand, EM ;

Nunez, O ;

Boss, C ;

Young, NS .

BLOOD, 2003, 102 (10) :3584-3586

[6] Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European blood and marrow transplant (EBMT) severe aplastic anaemia working party [J].

Marsh, J ;

Schrezenmeier, H ;

Marin, P ;

Ilhan, O ;

Ljungman, P ;

McCann, S ;

Socie, G ;

Tichelli, A ;

Passweg, J ;

Hows, J ;

Raghavachar, A ;

Locasciulli, A ;

Bacigalupo, A .

BLOOD, 1999, 93 (07) :2191-2195

[7]

MONIKA F, 2005, BLOOD, V106, P2102

[8] INTENSIVE IMMUNOSUPPRESSION WITH ANTITHYMOCYTE GLOBULIN AND CYCLOSPORINE AS TREATMENT FOR SEVERE ACQUIRED APLASTIC-ANEMIA [J].

ROSENFELD, SJ ;

KIMBALL, J ;

VINING, D ;

YOUNG, NS .

BLOOD, 1995, 85 (11) :3058-3065

[9]

SEIJI K, 2000, BLOOD, V96, P2049

[10]

XIAOTIAN X, 2006, CHIN J CONT PEDIAT, V6, P492

← 1 2 →